DPHA — Disruptive Pharma AB (publ) Share Price
Last trade - 00:00- SEK21.98m
- -SEK12.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.43 | ||
| PEG Ratio (f) | 0.01 | ||
| EPS Growth (f) | 263.92% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | 0.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -154.63% | ||
| Return on Equity | -94.39% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | 123,000 | 123,000 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +13.04 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Disruptive Pharma AB (publ), formerly Guard Therapeutics International AB (publ), is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.
Directors
- Cristina Glad CHM (67)
- Tobias Larsson Agervald CEO
- Torun Labedzki CFO
- Elisabeth Augustsson OTH (55)
- Lars Hockenstrom OTH
- Fredrik Lehmann OTH (44)
- Ann-Kristin Myde OTH (66)
- Ronny Renfurm OTH
- Michael Reusch OTH
- Sara Thuresson OTH
- Peter Gilmour MGB
- Goran Forsberg DRC (56)
- Johannes Hulthe DRC
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- April 4th, 2008
- Public Since
- April 3rd, 2013
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 20,167,631
- Address
- Guard Therapeutics, Nybrogatan 34, 2 tr, STOCKHOLM, 114 39
- Web
- https://guardtherapeutics.com/
- Phone
- +46 86706551
- Contact
- Ingmar Rentzhog
- Auditors
- PricewaterhouseCoopers AB
Latest News for DPHA
Upcoming Events for DPHA
Q3 2026 Guard Therapeutics International AB (publ) Earnings Release
Q4 2026 Guard Therapeutics International AB (publ) Earnings Release
Similar to DPHA
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
Alzinova AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 02:18 UTC, shares in Disruptive Pharma AB (publ) are trading at SEK1.09. This share price information is delayed by 15 minutes.
Shares in Disruptive Pharma AB (publ) last closed at SEK1.09 and the price had moved by -94.68% over the past 365 days. In terms of relative price strength the Disruptive Pharma AB (publ) share price has underperformed the FTSE Global All Cap Index by -95.27% over the past year.
The overall consensus recommendation for Disruptive Pharma AB (publ) is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDisruptive Pharma AB (publ) does not currently pay a dividend.
Disruptive Pharma AB (publ) does not currently pay a dividend.
Disruptive Pharma AB (publ) does not currently pay a dividend.
To buy shares in Disruptive Pharma AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK1.09, shares in Disruptive Pharma AB (publ) had a market capitalisation of SEK21.98m.
Here are the trading details for Disruptive Pharma AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: DPHA
Based on an overall assessment of its quality, value and momentum Disruptive Pharma AB (publ) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Disruptive Pharma AB (publ) is SEK1.50. That is 37.61% above the last closing price of SEK1.09.
Analysts covering Disruptive Pharma AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of SEK2.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Disruptive Pharma AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -15.68%.
As of the last closing price of SEK1.09, shares in Disruptive Pharma AB (publ) were trading -24.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Disruptive Pharma AB (publ) PE ratio based on its reported earnings over the past 12 months is 0.43. The shares last closed at SEK1.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Disruptive Pharma AB (publ)'s management team is headed by:
- Cristina Glad - CHM
- Tobias Larsson Agervald - CEO
- Torun Labedzki - CFO
- Elisabeth Augustsson - OTH
- Lars Hockenstrom - OTH
- Fredrik Lehmann - OTH
- Ann-Kristin Myde - OTH
- Ronny Renfurm - OTH
- Michael Reusch - OTH
- Sara Thuresson - OTH
- Peter Gilmour - MGB
- Goran Forsberg - DRC
- Johannes Hulthe - DRC